Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

The prognosis of biliary tract cancer (BTC) remains unsatisfactory. This single-arm, phase II clinical trial (ChiCTR2000036652) investigated the efficacy, safety, and predictive biomarkers of sintilimab plus gemcitabine and cisplatin as the first-line treatment for patients with advanced BTCs. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Tian-mei, Yang, Guang, Lou, Cheng, Wei, Wei, Tao, Chen-jie, Chen, Xi-yun, Han, Qin, Cheng, Zhuo, Shang, Pei-pei, Dong, Yu-long, Xu, He-ming, Guo, Lie-ping, Chen, Dong-sheng, Song, Yun-jie, Qi, Chuang, Deng, Wang-long, Yuan, Zhen-gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008621/
https://www.ncbi.nlm.nih.gov/pubmed/36906670
http://dx.doi.org/10.1038/s41467-023-37030-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008621/
https://www.ncbi.nlm.nih.gov/pubmed/36906670
http://dx.doi.org/10.1038/s41467-023-37030-w

Ejemplares similares